Featured conditions Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Featured conditions
Tab Title Description
The purpose of this study is to establish a centralized biobank of biospecimens (biofluids and tumor tissues) collected from patients with urologic cancers which will accelerate liquid biopsy research and the development of next-generation cell-based therapies.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
Inclusion Criteria:
Diagnosis of prostate cancer.
Diagnosis of suspicious renal masses/or kidney cancer.
Diagnosis of urothelial carcinoma.
Exclusion Criteria:
Unable or unwilling to provide informed consent.
Note: Other protocol defined Inclusion/Exclusion Criteria may apply.
Eligibility last updated 8/20/2025. Questions regarding updates should be directed to the study team contact
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
Mayo Clinic principal investigator
Fabrice Lucien-Matteoni, Ph.D.
Open for enrollment
Kelsey Bellman
5072667811
Contact Usbellman.kelsey@mayo.edu